Multiple Sclerosis and Related Disorders

Therapy relevant pathomechanisms in neuroimmunology 1:41
Therapy relevant pathomechanisms in neuroimmunology
Hans Lassmann • 27 Jun 2022
AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation 6:02
AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation
Klaus Schmierer • 1 Jul 2022
Targeting paramagnetic rim lesions in multiple sclerosis 2:10
Targeting paramagnetic rim lesions in multiple sclerosis
Alberto Calvi • 6 Jul 2022
The relationship between slowly expanding lesions and paramagnetic rim lesions in multiple sclerosis 6:47
The relationship between slowly expanding lesions and paramagnetic rim lesions in multiple sclerosis
Alberto Calvi • 6 Jul 2022
Increasing incidence and prevalence of MS in Tasmania, Australia 5:11
Increasing incidence and prevalence of MS in Tasmania, Australia
Steve Simpson-Yap • 29 Jun 2022
Developing biomarkers for individual prognostication in MS 3:34
Developing biomarkers for individual prognostication in MS
Klaus Schmierer • 1 Jul 2022
Early diagnosis and treatment for multiple sclerosis prevention 2:44
Early diagnosis and treatment for multiple sclerosis prevention
Klaus Schmierer • 1 Jul 2022
Slowly expanding lesions as predictive biomarkers in MS 6:14
Slowly expanding lesions as predictive biomarkers in MS
Alberto Calvi • 6 Jul 2022
What underlies the increased prevalence and incidence of multiple sclerosis in Tasmania? 2:25
What underlies the increased prevalence and incidence of multiple sclerosis in Tasmania?
Steve Simpson-Yap • 29 Jun 2022
ChariotMS: the first DMT trial in advanced multiple sclerosis 3:19
ChariotMS: the first DMT trial in advanced multiple sclerosis
Klaus Schmierer • 1 Jul 2022
The developing role of vitamin D and sun exposure in multiple sclerosis onset and clinical course 2:40
The developing role of vitamin D and sun exposure in multiple sclerosis onset and clinical course
Steve Simpson-Yap • 29 Jun 2022
sNfL as a prognostic biomarker of MS at an individual level 0:59
sNfL as a prognostic biomarker of MS at an individual level
Jens Kuhle • 26 Jun 2022
The potential of sNfL as an exploratory endpoint for MS trials 1:03
The potential of sNfL as an exploratory endpoint for MS trials
Jens Kuhle • 26 Jun 2022
Strategies to address the burden of MS from the individual and societal perspectives 2:52
Strategies to address the burden of MS from the individual and societal perspectives
Giancarlo Comi • 27 Jun 2022
Sex differences in multiple sclerosis disease course over 25 years of follow up 4:53
Sex differences in multiple sclerosis disease course over 25 years of follow up
Melinda Magyari • 8 Apr 2022
The effects of cardiovascular comorbidities on clinical and cognitive measures of multiple sclerosis 1:15
The effects of cardiovascular comorbidities on clinical and cognitive measures of multiple sclerosis
Dejan Jakimovski • 4 Apr 2022
The content of VJNeurology is intended for healthcare professionals